HIV treatment as prevention among injection drug usersWood, Evana,b; Milloy, Michael Johna; Montaner, Julio S.G.a,bCurrent Opinion in HIV & AIDS: March 2012 - Volume 7 - Issue 2 - p 151–156 doi: 10.1097/COH.0b013e32834f9927 TEST AND TREAT: Edited by Ann Duerr Abstract Author Information Purpose of review: The use of highly active antiretroviral therapy (HAART) as a strategy to prevent the transmission of HIV infection is of substantial international interest. Injection drug users (IDUs) are an important population with respect to HIV treatment as prevention because they are often less likely to access HAART in comparison with other risk groups. Recent findings: A recent multicentre randomized clinical trial demonstrated a 96% reduction in HIV transmission among heterosexual serodiscordant couples prescribed early HAART. Consistent with these results, independent observational studies from Baltimore and Vancouver have demonstrated that population level rates of HAART use among IDUs are associated with reduced rates of HIV incidence. In addition, impact assessments of HAART delivery to IDUs have generally demonstrated no negative effects of HAART use on rates of unsafe sex or syringe sharing. Summary: HAART prevents HIV transmission because it dramatically decreases HIV-1 RNA levels in biological fluids. This is relevant to vertical and sexual HIV transmission and also to blood-borne HIV transmission, as it is often the case among IDUs. Efforts to expand HAART to IDUs should be redoubled in an effort to realize both the individual and public health benefits of HAART. aBritish Columbia Centre for Excellence in HIV/AIDS, St. Paul's Hospital bFaculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada Correspondence to Evan Wood, MD, PhD, Urban Health Research Initiative, British Columbia Centre for Excellence in HIV/AIDS, 608-1081 Burrard Street, Vancouver, BC V6Z 1Y6, Canada. Tel: +1 604 806 9692; fax: +1 604 806 9044; e-mail: firstname.lastname@example.org © 2012 Lippincott Williams & Wilkins, Inc.